{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:58:38Z","timestamp":1775239118153,"version":"3.50.1"},"reference-count":134,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2026,3,14]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Currently available pharmacotherapies for interstitial lung disease (ILD) are limited to systemic glucocorticoids, steroid-sparing immunosuppressive medications and antifibrotic medications. Each of these treatments target major components of ILD biology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This review presents the relevant evidence to the pharmacological management of ILD that is based on a treatable traits approach. We further highlight major knowledge gaps that should be the focus of future research that moves patient care toward a more precision-medicine approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary of review<\/jats:title>\n                    <jats:p>The previous treatment paradigm for the pharmacotherapy of ILD is based on the integration of several clinical, laboratory, radiological and pathological features to an underlying biology that is more likely to respond to a given medication strategy. Patients with more acute presentations and suggestion of significant inflammation are typically treated with systemic glucocorticoid therapy, with the route and initial dose decided primarily based on the severity of disease. Patients with ILD who have chronic disease with suggestion of inflammatory features are typically treated with long-term steroid-sparing immunosuppression. Patients with ILD who have chronic disease with progressive fibrotic features are typically treated with antifibrotic medication. Emerging therapies include nerandomilast, a phosphodiesterase 4B inhibitor with antifibrotic and immunomodulatory effects that has recently been approved in the USA. A major goal is future integration of molecular endotypes to support a transition towards precision-based management of ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pharmacotherapy of ILD has previously focused on a morphology-based treatable traits approach that uses various clinical, laboratory, radiological and pathological clues to suggest a preferred treatment. We describe this approach and highlight specific questions that need to be addressed in future studies as we move toward a precision-based approach to patient management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2024-222058","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:20:30Z","timestamp":1775236830000},"page":"thorax-2024-222058","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Treatable traits in interstitial lung disease: towards precision medicine"],"prefix":"10.1136","author":[{"given":"Na\u2019ama","family":"Avitzur","sequence":"first","affiliation":[{"name":"Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3358-7699","authenticated-orcid":false,"given":"Daniel-Costin","family":"Marinescu","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada"},{"name":"Centre for Lung Health, Vancouver General Hospital, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Churg","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Goobie","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada"},{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"Hague","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nestor L","family":"Muller","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne L","family":"Wright","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1049-393X","authenticated-orcid":false,"given":"Christopher J","family":"Ryerson","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"2026040310202702000_thorax-2024-222058v1.1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.2.ats3-00"},{"key":"2026040310202702000_thorax-2024-222058v1.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113354"},{"key":"2026040310202702000_thorax-2024-222058v1.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"2026040310202702000_thorax-2024-222058v1.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2026040310202702000_thorax-2024-222058v1.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120"},{"key":"2026040310202702000_thorax-2024-222058v1.6","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2026040310202702000_thorax-2024-222058v1.7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026040310202702000_thorax-2024-222058v1.8","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026040310202702000_thorax-2024-222058v1.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2026040310202702000_thorax-2024-222058v1.10","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026040310202702000_thorax-2024-222058v1.11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026040310202702000_thorax-2024-222058v1.12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026040310202702000_thorax-2024-222058v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2020.03.009"},{"key":"2026040310202702000_thorax-2024-222058v1.14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072269","article-title":"Alveolar Epithelial Type II Cells as Drivers of Lung Fibrosis in Idiopathic Pulmonary Fibrosis","volume":"21","author":"Parimon","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026040310202702000_thorax-2024-222058v1.15","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2019.109482","article-title":"The leading role of epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis","volume":"66","author":"Selman","year":"2020","journal-title":"Cell Signal"},{"key":"2026040310202702000_thorax-2024-222058v1.16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04507-2020","article-title":"When things go wrong: exploring possible mechanisms driving the progressive fibrosis phenotype in interstitial lung diseases","volume":"58","author":"Selman","year":"2021","journal-title":"Eur Respir J"},{"key":"2026040310202702000_thorax-2024-222058v1.17","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.1.3"},{"key":"2026040310202702000_thorax-2024-222058v1.18","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201903-0541PP"},{"key":"2026040310202702000_thorax-2024-222058v1.19","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/art.40574","article-title":"The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease","volume":"70","author":"Spagnolo","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2026040310202702000_thorax-2024-222058v1.20","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00441-2023","article-title":"Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease","volume":"62","author":"Zhang","year":"2023","journal-title":"Eur Respir J"},{"key":"2026040310202702000_thorax-2024-222058v1.21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01011-2016","article-title":"Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures","volume":"49","author":"Jacob","year":"2017","journal-title":"Eur Respir J"},{"key":"2026040310202702000_thorax-2024-222058v1.22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202112-2684OC"},{"key":"2026040310202702000_thorax-2024-222058v1.23","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201711-2174OC"},{"key":"2026040310202702000_thorax-2024-222058v1.24","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201905-1017OC"},{"key":"2026040310202702000_thorax-2024-222058v1.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013660"},{"key":"2026040310202702000_thorax-2024-222058v1.26","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1164\/rccm.202205-0845OC","article-title":"PCSK6 and Survival in Idiopathic Pulmonary Fibrosis","volume":"207","author":"Oldham","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026040310202702000_thorax-2024-222058v1.27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00308-2016"},{"key":"2026040310202702000_thorax-2024-222058v1.28","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.chest.2022.11.002","article-title":"Progressive Disease With Low Survival in Adult Patients With Pulmonary Fibrosis Carrying Surfactant-Related Gene Mutations: An Observational Study","volume":"163","author":"Klay","year":"2023","journal-title":"Chest"},{"key":"2026040310202702000_thorax-2024-222058v1.29","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02571-2021"},{"key":"2026040310202702000_thorax-2024-222058v1.30","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00092309"},{"key":"2026040310202702000_thorax-2024-222058v1.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.08.1076"},{"key":"2026040310202702000_thorax-2024-222058v1.32","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00016-2017","article-title":"Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis","volume":"3","author":"Adegunsoye","year":"2017","journal-title":"ERJ Open Res"},{"key":"2026040310202702000_thorax-2024-222058v1.33","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.chest.2023.12.019","article-title":"Impact of Antigen Exposure on Outcomes and Treatment Response in Fibrotic Hypersensitivity Pneumonitis","volume":"165","author":"Mullin","year":"2024","journal-title":"Chest"},{"key":"2026040310202702000_thorax-2024-222058v1.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414108"},{"key":"2026040310202702000_thorax-2024-222058v1.35","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","article-title":"Nerandomilast in Patients with Progressive Pulmonary Fibrosis","volume":"392","author":"Maher","year":"2025","journal-title":"N Engl J Med"},{"key":"2026040310202702000_thorax-2024-222058v1.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0371-y"},{"key":"2026040310202702000_thorax-2024-222058v1.37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208916"},{"key":"2026040310202702000_thorax-2024-222058v1.38","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases","volume":"76","author":"Johnson","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026040310202702000_thorax-2024-222058v1.39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0313540","article-title":"Clinical predictors of physiologic change after treatment with immunosuppression in hypersensitivity pneumonitis","volume":"19","author":"Kypreos","year":"2024","journal-title":"PLoS One"},{"key":"2026040310202702000_thorax-2024-222058v1.40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/resp.13230","article-title":"Unfavourable outcome of glucocorticoid treatment in suspected idiopathic pulmonary fibrosis","volume":"23","author":"Wiertz","year":"2018","journal-title":"Respirology"},{"key":"2026040310202702000_thorax-2024-222058v1.41","first-page":"1476","article-title":"Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparison of the clinicopathologic features and prognosis","volume":"6","author":"Li","year":"2014","journal-title":"J Thorac Dis"},{"key":"2026040310202702000_thorax-2024-222058v1.42","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0801CI"},{"key":"2026040310202702000_thorax-2024-222058v1.43","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201809-1646OC"},{"key":"2026040310202702000_thorax-2024-222058v1.44","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-021-06394-2"},{"key":"2026040310202702000_thorax-2024-222058v1.45","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01983-2019","article-title":"Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in fibrotic hypersensitivity pneumonitis: a retrospective cohort study","volume":"55","author":"De Sadeleer","year":"2020","journal-title":"Eur Respir J"},{"key":"2026040310202702000_thorax-2024-222058v1.46","first-page":"1527","article-title":"Corticosteroid resistant interstitial pneumonitis in dermatomyositis\/polymyositis: prediction and treatment with cyclosporine","volume":"26","author":"Nawata","year":"1999","journal-title":"J Rheumatol"},{"key":"2026040310202702000_thorax-2024-222058v1.47","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202005-2032ST"},{"key":"2026040310202702000_thorax-2024-222058v1.48","doi-asserted-by":"publisher","DOI":"10.1148\/rg.291085096"},{"key":"2026040310202702000_thorax-2024-222058v1.49","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.chest.2021.12.659","article-title":"Algorithmic Approach to the Diagnosis of Organizing Pneumonia: A Correlation of Clinical, Radiologic, and Pathologic Features","volume":"162","author":"Cherian","year":"2022","journal-title":"Chest"},{"key":"2026040310202702000_thorax-2024-222058v1.50","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.140574"},{"key":"2026040310202702000_thorax-2024-222058v1.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2014.11.026"},{"key":"2026040310202702000_thorax-2024-222058v1.52","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.173.4.10511155"},{"key":"2026040310202702000_thorax-2024-222058v1.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2004.06.029"},{"key":"2026040310202702000_thorax-2024-222058v1.54","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/RCT.0b013e31822a5883","article-title":"Nonspecific interstitial pneumonia: prognostic significance of high-resolution computed tomography in 59 patients","volume":"35","author":"Hozumi","year":"2011","journal-title":"J Comput Assist Tomogr"},{"key":"2026040310202702000_thorax-2024-222058v1.55","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.189.3.8234692"},{"key":"2026040310202702000_thorax-2024-222058v1.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.03.066"},{"key":"2026040310202702000_thorax-2024-222058v1.57","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00158-2025","article-title":"Update of the International Multidisciplinary Classification of the Interstitial Pneumonias: An ERS\/ATS Statement","volume":"66","author":"Ryerson","year":"2025","journal-title":"Eur Respir J"},{"key":"2026040310202702000_thorax-2024-222058v1.58","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.168.1.8976924"},{"key":"2026040310202702000_thorax-2024-222058v1.59","doi-asserted-by":"publisher","DOI":"10.1097\/01.rti.0000213588.52343.13"},{"key":"2026040310202702000_thorax-2024-222058v1.60","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-011-2211-6"},{"key":"2026040310202702000_thorax-2024-222058v1.61","doi-asserted-by":"publisher","DOI":"10.1148\/rg.306105512"},{"key":"2026040310202702000_thorax-2024-222058v1.62","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1148\/radiology.189.1.8372213","article-title":"Ground-glass attenuation, nodules, alveolitis, and sarcoid granulomas","volume":"189","author":"M\u00fcller","year":"1993","journal-title":"Radiology"},{"key":"2026040310202702000_thorax-2024-222058v1.63","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2214\/ajr.159.3.1503008","article-title":"Pulmonary sarcoidosis: changes on follow-up CT examination","volume":"159","author":"Murdoch","year":"1992","journal-title":"AJR Am J Roentgenol"},{"key":"2026040310202702000_thorax-2024-222058v1.64","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S2213-2600(23)00267-9","article-title":"High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study","volume":"12","author":"Desai","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026040310202702000_thorax-2024-222058v1.65","first-page":"154","article-title":"Predicting respiratory failure in sarcoidosis patients","volume":"14","author":"Baughman","year":"1997","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026040310202702000_thorax-2024-222058v1.66","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O"},{"key":"2026040310202702000_thorax-2024-222058v1.67","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker271"},{"key":"2026040310202702000_thorax-2024-222058v1.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.10.029"},{"key":"2026040310202702000_thorax-2024-222058v1.69","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1513\/AnnalsATS.202108-954RL","article-title":"Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease","volume":"19","author":"Wong","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"2026040310202702000_thorax-2024-222058v1.70","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-022-02292-3"},{"key":"2026040310202702000_thorax-2024-222058v1.71","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/resp.14301","article-title":"Clinical relevance of rheumatoid factor and anti\u2010citrullinated peptides in fibrotic interstitial lung disease","volume":"27","author":"Zheng","year":"2022","journal-title":"Respirology"},{"key":"2026040310202702000_thorax-2024-222058v1.72","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01806-2023","article-title":"Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease","volume":"63","author":"Mackintosh","year":"2024","journal-title":"Eur Respir J"},{"key":"2026040310202702000_thorax-2024-222058v1.73","doi-asserted-by":"crossref","first-page":"960","DOI":"10.5858\/arpa.2016-0427-OA","article-title":"Interstitial Pneumonia With Autoimmune Features: Value of Histopathology","volume":"141","author":"Adegunsoye","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"2026040310202702000_thorax-2024-222058v1.74","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000885"},{"key":"2026040310202702000_thorax-2024-222058v1.75","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.5858\/arpa.2019-0628-RA","article-title":"Centrilobular Fibrosis in Fibrotic (Chronic) Hypersensitivity Pneumonitis, Usual Interstitial Pneumonia, and Connective Tissue Disease\u2013Associated Interstitial Lung Disease","volume":"144","author":"Churg","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"2026040310202702000_thorax-2024-222058v1.76","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1183\/16000617.0210-2022","article-title":"Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis","volume":"32","author":"Joy","year":"2023","journal-title":"Eur Respir Rev"},{"key":"2026040310202702000_thorax-2024-222058v1.77","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/resp.13978","article-title":"Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis\/dermatomyositis-associated ILD: A randomized, open-label trial","volume":"26","author":"Fujisawa","year":"2021","journal-title":"Respirology"},{"key":"2026040310202702000_thorax-2024-222058v1.78","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01488-2024","article-title":"Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study","volume":"65","author":"Wu","year":"2025","journal-title":"Eur Respir J"},{"key":"2026040310202702000_thorax-2024-222058v1.79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1900045"},{"key":"2026040310202702000_thorax-2024-222058v1.80","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1183\/16000617.0169-2021","article-title":"Diagnosis, course and management of hypersensitivity pneumonitis","volume":"31","author":"Hamblin","year":"2022","journal-title":"Eur Respir Rev"},{"key":"2026040310202702000_thorax-2024-222058v1.81","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00174914"},{"key":"2026040310202702000_thorax-2024-222058v1.82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2008.06.046"},{"key":"2026040310202702000_thorax-2024-222058v1.83","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"2026040310202702000_thorax-2024-222058v1.84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2026040310202702000_thorax-2024-222058v1.85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2026040310202702000_thorax-2024-222058v1.86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076"},{"key":"2026040310202702000_thorax-2024-222058v1.87","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2213-2600(18)30135-8","article-title":"Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study","volume":"6","author":"Dressen","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026040310202702000_thorax-2024-222058v1.88","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-01582-y"},{"key":"2026040310202702000_thorax-2024-222058v1.89","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10173864","article-title":"Serial Measurements of Circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and Periostin in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Therapy: An Exploratory Study","volume":"10","author":"Majewski","year":"2021","journal-title":"J Clin Med"},{"key":"2026040310202702000_thorax-2024-222058v1.90","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1483ST"},{"key":"2026040310202702000_thorax-2024-222058v1.91","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2016152362"},{"key":"2026040310202702000_thorax-2024-222058v1.92","doi-asserted-by":"crossref","DOI":"10.1148\/ryct.230135","article-title":"Thin-Section CT in the Categorization and Management of Pulmonary Fibrosis including Recently Defined Progressive Pulmonary Fibrosis","volume":"6","author":"Shah","year":"2024","journal-title":"Radiol Cardiothorac Imaging"},{"key":"2026040310202702000_thorax-2024-222058v1.93","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.189.3.8080483"},{"key":"2026040310202702000_thorax-2024-222058v1.94","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.184.2.1620845"},{"key":"2026040310202702000_thorax-2024-222058v1.95","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.241001","article-title":"CT Honeycombing and Traction Bronchiectasis Extent Independently Predict Survival across Fibrotic Interstitial Lung Disease Subtypes","volume":"314","author":"Marinescu","year":"2025","journal-title":"Radiology"},{"key":"2026040310202702000_thorax-2024-222058v1.96","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.05.002"},{"key":"2026040310202702000_thorax-2024-222058v1.97","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.162.6.2003049"},{"key":"2026040310202702000_thorax-2024-222058v1.98","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2106012"},{"key":"2026040310202702000_thorax-2024-222058v1.99","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.1.22"},{"key":"2026040310202702000_thorax-2024-222058v1.100","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2008.01.012"},{"key":"2026040310202702000_thorax-2024-222058v1.101","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-2572"},{"key":"2026040310202702000_thorax-2024-222058v1.102","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/pin.13511","article-title":"Pathological predictor of progressive pulmonary fibrosis","volume":"75","author":"Ahn","year":"2025","journal-title":"Pathol Int"},{"key":"2026040310202702000_thorax-2024-222058v1.103","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1513\/AnnalsATS.202102-198OC","article-title":"Use of a Genomic Classifier in Patients with Interstitial Lung Disease: A Systematic Review and Meta-Analysis","volume":"19","author":"Kheir","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"2026040310202702000_thorax-2024-222058v1.104","doi-asserted-by":"crossref","first-page":"106722","DOI":"10.1016\/j.rmed.2021.106722","article-title":"Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study","volume":"191","author":"Adams","year":"2022","journal-title":"Respir Med"},{"key":"2026040310202702000_thorax-2024-222058v1.105","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1164\/rccm.202403-0636OC","article-title":"Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial","volume":"210","author":"Lancaster","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026040310202702000_thorax-2024-222058v1.106","unstructured":"Christopher Keenan PT . Pliant Therapeutics Provides Update on BEACON-IPF. 2025."},{"key":"2026040310202702000_thorax-2024-222058v1.107","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202112-2824OC"},{"key":"2026040310202702000_thorax-2024-222058v1.108","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1164\/rccm.202405-0977OC","article-title":"Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial","volume":"211","author":"Corte","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026040310202702000_thorax-2024-222058v1.109","unstructured":"Corporation UT . United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso\u00ae Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis."},{"key":"2026040310202702000_thorax-2024-222058v1.110","doi-asserted-by":"crossref","first-page":"104766","DOI":"10.1016\/j.ebiom.2023.104766","article-title":"Precision medicine advances in idiopathic pulmonary fibrosis","volume":"95","author":"Karampitsakos","year":"2023","journal-title":"EBioMedicine"},{"key":"2026040310202702000_thorax-2024-222058v1.111","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-022-02281-8","article-title":"Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial","volume":"22","author":"Podolanczuk","year":"2022","journal-title":"BMC Pulm Med"},{"key":"2026040310202702000_thorax-2024-222058v1.112","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201505-1010OC"},{"key":"2026040310202702000_thorax-2024-222058v1.113","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S2213-2600(17)30349-1","article-title":"Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study","volume":"5","author":"Herazo-Maya","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026040310202702000_thorax-2024-222058v1.114","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1164\/rccm.202301-0117OC","article-title":"Proteomic Biomarkers of Survival in Idiopathic Pulmonary Fibrosis","volume":"209","author":"Oldham","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026040310202702000_thorax-2024-222058v1.115","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1164\/rccm.202310-1887OC","article-title":"Biological Age, Chronological Age, and Survival in Pulmonary Fibrosis: A Causal Mediation Analysis","volume":"210","author":"Pugashetti","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026040310202702000_thorax-2024-222058v1.116","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01618-2024","article-title":"Accelerated epigenetic ageing worsens survival and mediates environmental stressors in fibrotic interstitial lung disease","volume":"65","author":"Goobie","year":"2025","journal-title":"Eur Respir J"},{"key":"2026040310202702000_thorax-2024-222058v1.117","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02042-2020","article-title":"Exhaled breath analysis by use of eNose technology: a novel diagnostic tool for interstitial lung disease","volume":"57","author":"Moor","year":"2021","journal-title":"Eur Respir J"},{"key":"2026040310202702000_thorax-2024-222058v1.118","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.91377","article-title":"3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs","volume":"2","author":"Surolia","year":"2017","journal-title":"JCI Insight"},{"key":"2026040310202702000_thorax-2024-222058v1.119","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208929"},{"key":"2026040310202702000_thorax-2024-222058v1.120","doi-asserted-by":"crossref","DOI":"10.1016\/j.medcli.2025.107206","article-title":"Quantitative analysis of chest CT with deep learning to assess the efficacy of tofacitinib in the treatment of anti-MDA5+ dermatomyositis","volume":"165","author":"You","year":"2025","journal-title":"Medicina Cl\u00ednica"},{"key":"2026040310202702000_thorax-2024-222058v1.121","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1093\/rheumatology\/kead642","article-title":"Lung ultrasound and high-resolution computed tomography quantitative variations during nintedanib treatment for systemic sclerosis-associated interstitial lung disease","volume":"63","author":"Di Battista","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026040310202702000_thorax-2024-222058v1.122","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.11.033"},{"key":"2026040310202702000_thorax-2024-222058v1.123","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.08.2043"},{"key":"2026040310202702000_thorax-2024-222058v1.124","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S2213-2600(25)00159-6","article-title":"Persisting CD19.CAR-T cells in combination with nintedanib: clinical response in a patient with systemic sclerosis-associated pulmonary fibrosis after 2 years","volume":"13","author":"Merkt","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026040310202702000_thorax-2024-222058v1.125","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703327"},{"key":"2026040310202702000_thorax-2024-222058v1.126","unstructured":"Association AL . Stem cell therapy (advisory). 2025. Available: https:\/\/www.lung.org\/lung-health-diseases\/wellness\/public-health-issues-lung-health\/stem-cell-therapy"},{"key":"2026040310202702000_thorax-2024-222058v1.127","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200318384"},{"key":"2026040310202702000_thorax-2024-222058v1.128","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.11.005"},{"key":"2026040310202702000_thorax-2024-222058v1.129","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)10310-X"},{"key":"2026040310202702000_thorax-2024-222058v1.130","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2009.02207.x"},{"key":"2026040310202702000_thorax-2024-222058v1.131","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur Respir J"},{"key":"2026040310202702000_thorax-2024-222058v1.132","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199512000-00007"},{"key":"2026040310202702000_thorax-2024-222058v1.133","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200955"},{"key":"2026040310202702000_thorax-2024-222058v1.134","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2019-0328TR"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2024-222058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:20:38Z","timestamp":1775236838000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2024-222058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":134,"alternative-id":["10.1136\/thorax-2024-222058"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2024-222058","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]}}}